Will osimertinib mesylate tablets cause resistance?

Osimertinib mesylate tablets, as a targeted therapy drug for non-small cell lung cancer (NSCLC), may indeed develop drug resistance during long-term use. With long-term use of Osimertinib mesylate tablets, tumor cells may gradually adapt to the drug environment and resist the effects of the drug through genetic mutations or other mechanisms, resulting in a decrease in drug efficacy, that is, the development of drug resistance.

According to clinical study data, the resistance time to osimertinib is usually about one and a half years. In global phase III clinical studies of osimertinib, disease progression typically occurred around 18.9 months, indicating the development of drug resistance.

Factors such as different patients' physical conditions, genetic background, and disease severity may affect the speed and extent of drug resistance. The way the drug is taken, the dose and whether it is used regularly may also have an impact on the development of drug resistance.

After resistance to osimertinib occurs, genetic testing should be performed to clarify the resistance mechanism, and the treatment plan should be adjusted based on the test results, such as switching to other targeted drugs or taking chemotherapy and other measures. To address the problem of drug resistance, doctors may adopt comprehensive treatment strategies, including combining drugs, changing medication methods, etc., to improve the treatment effect and delay the development of drug resistance.

Osimertinib mesylate tablets may indeed develop drug resistance during long-term use. In order to effectively deal with this problem, patients need to pay close attention to changes in their condition, conduct relevant examinations regularly, and adjust their medication regimen under the guidance of a doctor. At the same time, maintaining good living habits and mentality can also help delay the development of drug resistance and improve the quality of life.